Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma

INTRODUCTION: The present study aimed to inform an economic evaluation of dabrafenib and trametinib combination as first-line treatment of metastatic melanoma in a Canadian setting. A network meta-analysis was conducted to estimate hazard ratios (HRs) for progression-free survival (PFS)and overall s...

Descripción completa

Detalles Bibliográficos
Autores principales: Amdahl, Jordan, Chen, Lei, Delea, Thomas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315084/
https://www.ncbi.nlm.nih.gov/pubmed/28261653
http://dx.doi.org/10.1007/s40487-016-0030-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315084/
https://www.ncbi.nlm.nih.gov/pubmed/28261653
http://dx.doi.org/10.1007/s40487-016-0030-2

Ejemplares similares